GLP ‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation
Authors' conclusion
The convergence of escalating demand, widespread off-label use and product falsification requires a coordinated and agile regulatory response. The observed trends suggest significant access disparities driven by economic factors rather than epidemiological need.
Study context
- Population
- GLP-1 RA consumption, adverse event reports (Vigimed, integrated with VigiBase) and falsified-product alerts in Brazil; national sales 2020–2024
- Outcome
- Landscape of GLP-1 RA consumption, safety monitoring and regulation
- Follow-up
- 2020-2024
Methodological detailstriangulation of three official data sources, Sales data from industrial reports and the National System for the Management of Controlled Products (SNGPC), classified by Anatomical Therapeutic Chemical (ATC) system
- Triangulation of three official data sources
- Sales data from industrial reports and the National System for the Management of Controlled Products (SNGPC), classified by ATC system
Main finding
As reported in the abstract
- Semaglutide was the predominant GLP-1 RA in the Brazilian market
- Consumption markedly concentrated in regions with higher Gross Domestic Product (GDP); disconnect between medication use and regional diabetes prevalence
- Significant proportion of pharmacovigilance reports involved off-label use
- Documented cases of counterfeit products
Observational data: associations, not effects.
Safety
Pharmacovigilance reports and falsified products
- Significant proportion of adverse event reports involved off-label use; documented counterfeit products
Original publication
GLP ‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation. Diabetes Obes Metab. Published 8 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →